DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report published on Saturday. The firm issued a hold rating on the stock.

Separately, JMP Securities reiterated a “market outperform” rating and set a $10.00 price target on shares of DBV Technologies in a research report on Friday, January 10th.

DBV Technologies Stock Down 10.6 %

DBVT opened at $4.46 on Friday. The stock has a market capitalization of $91.74 million, a price-to-earnings ratio of -0.99 and a beta of 0.71. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $8.32. The company has a 50-day simple moving average of $4.46 and a 200 day simple moving average of $3.84.

Institutional Trading of DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC bought a new position in DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies at the end of the most recent quarter. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.